Inventor
NAGY KALMAN
HU23 patents
⚠️ This page may combine multiple inventors who share the name “NAGY KALMAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
EGYT GYOGYSZERVEGYESZETI GYAR
10 patentsUS6646133B1Nov 11, 2003
Process for the preparation of amorphous atorvastatin calcium
EGYT GYOGYSZERVEGYESZETI GYAR20 citations87
US5155260AOct 13, 1992
Process for the preparation of 2,2-dimethyl-5-(2,5-dimethyl-phenoxy)-pentanoic acid, intermediates for preparing this compound and process for preparing the intermediates
EGYT GYOGYSZERVEGYESZETI GYAR14 citations70
US7186848B2Mar 6, 2007
Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin
EGYT GYOGYSZERVEGYESZETI GYAR3 citations58
US5473072ADec 5, 1995
Process for the preparation of high purity buspiron and the hydrochloride thereof
EGYT GYOGYSZERVEGYESZETI GYAR3 citations57
US7307168B2Dec 11, 2007
Process for the preparation of 3-{2-′4- (6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyllethyl}-6,7,8,9-tetrahydro-2-methyl-4h-pyrido′1,2-methyl-4h-pyrido′,2-a!pyrimidin-4-one
EGYT GYOGYSZERVEGYESZETI GYAR2 citations56
US5235097AAug 10, 1993
Process for the preparation of 2,2-dimethyl-5-(2,5-dimethyl-phenoxy)-pentanoic acid, intermediates for preparing this compound and process for preparing the intermediates
EGYT GYOGYSZERVEGYESZETI GYAR1 citations48
US6908999B2Jun 21, 2005
Process for the preparation of {2-[4-α-phenyl-p-chlorobenzyl)piperazin-1-yl]ethoxy} acetic acid and novel intermediates therefor
EGYT GYOGYSZERVEGYESZETI GYAR1 citations46
US7396931B2Jul 8, 2008
Process for the preparation of amorphous form of a platelet aggregation inhibitor drug
EGYT GYOGYSZERVEGYESZETI GYAR0 citations45
US5216157AJun 1, 1993
1,4,Dihydro-pyridine intermediates
EGYT GYOGYSZERVEGYESZETI GYAR1 citations45
US5126457AJun 30, 1992
Process for the preparation of 1,4-dihydro-pyridine derivatives
EGYT GYOGYSZERVEGYESZETI GYAR1 citations45
ORION CORP
2 patentsUS6335469B1Jan 1, 2002
High purity (1R,2S,4R)-(-)-2-[(2′-{N,N-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]-bicyclo[2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof
ORION CORP4 citations71
US6624201B2Sep 23, 2003
High purity (1r,2s,4r)-(−)-2-[(2′-{n,n-dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7 -tri-[methyl]-bicyclo [2.2.1]heptane and pharmaceutically acceptable acid addition salts thereof and a process for the preparation of these compounds as well as medicaments containing 1 or more of these compounds and their use
ORION CORP1 citations60
EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG
2 patentsUS7851627B2Dec 14, 2010
Optically active carbamates, process for preparation thereof and use thereof as pharmaceutical intermediates
EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG3 citations53
US7981884B2Jul 19, 2011
Process for the preparation of olanzapine
EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG0 citations40